Terminated PHASE2 INTERVENTIONAL 1-arm NCT01528501

Histone Deacetylases - Gastric Cancer (HDAC-GaCa-2008) (HDAC)

An Open-label, Uncontrolled Phase II Trial of HDAC-Inhibitor LBH589 in Patients With Chemo-refractory Metastatic Gastric Cancer Overexpressing Histone Deacetylases (HDACs) - CLBH589BDE03T

Sponsor: Novartis

Conditions Metastatic Gastric Cancer

Interventions Panobinostat (LBH589)

Updated 7 times since 2017 Last updated: Apr 30, 2013 Started: Jun 30, 2009 Primary completion: Feb 28, 2013

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

medical/ethical reasons

Other terminated trials from Novartis

See all terminations from Novartis

A PHASE2 clinical study on Metastatic Gastric Cancer, this trial is terminated or withdrawn. The trial is conducted by Novartis and has accumulated 7 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Terminated PHASE2
Sep 2024 — Sep 2025 [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Nov 2022 — Jul 2024 [monthly]

Terminated PHASE2
Jan 2021 — Nov 2022 [monthly]

Terminated PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Jun 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Novartis
Technical University of Munich

Data source: Technical University of Munich

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Mannheim, Germany
• Munich, Germany